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Abstract The cardiac extracellular matrix (ECM) fills the
space between cells, supports tissue organization, and trans-
duces mechanical, chemical, and biological signals to regulate
homeostasis of the left ventricle (LV). Following myocardial
infarction (MI), a multitude of ECM proteins are synthesized to
replace myocyte loss and form a reparative scar. Activated
fibroblasts (myofibroblasts) are the primary source of ECM
proteins, thus playing a key role in cardiac repair. A balanced
turnover of ECM through regulation of synthesis by
myofibroblasts and degradation by matrix metalloproteinases
(MMPs) is critical for proper scar formation. In this review, we
summarize the current literature on the roles of myofibroblasts,
MMPs, and ECM proteins in MI-induced LV remodeling. In
addition, we discuss future research directions that are needed to
further elucidate the molecular mechanisms of ECM actions to
optimize cardiac repair.
Keywords Extracellular matrix . MMP-9 .Myocardial
infarction .Myofibroblast . Proteomics . Review
Introduction
Cardiovascular disease is an increasing burden worldwide,
and myocardial infarction (MI) contributes significantly to
morbidity and mortality. In-hospital survival for MI patients
has greatly improved over the past three decades due to the
introduction of reperfusion and other therapeutic strategies.
However, as short-term survival after acute MI has improved,
the incidence of heart failure post-MI has risen [34]. In response
to MI, the left ventricle (LV) undergoes a series of changes in
geometry and function, a process termed LV remodeling. Un-
derstanding the mechanisms of adverse LV remodeling is crit-
ical to our effort to improve long-term outcome after MI.
After 30 min of ischemia, cardiomyocytes undergo irrevers-
ible cell death, which induces an acute inflammatory response
through upregulation of the complement pathway. Neutrophils
and macrophages sequentially infiltrate the infarct region and
release inflammatory mediators and matrix metalloproteinases
(MMPs) to degrade extracellular matrix (ECM) and engulf
tissue debris [70]. The LV has limited regenerative capacity,
and a collagen-rich reparative scar is formed to replace the
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extensive loss of cardiomyocytes in the infarct zone [68].
Myofibroblasts are the major source of ECM in the scar. In
response to inflammatory mediators, resident cardiac fibro-
blasts and other cell lineages are stimulated to differentiate into
myofibroblasts, which results in abundant ECM synthesis and
deposition [106]. The proper balance between ECM synthesis
and degradation is critical for optimal infarct healing. Endoge-
nous tissue inhibitors of metalloproteinases (TIMPs) block
excessive MMP activity and play a key role in maintaining
the balance between ECM synthesis and degradation. Excessive
ECM accumulation increases wall stiffness and impairs compli-
ance, leading to diastolic dysfunction, whereas inadequate ECM
deposition and impaired collagen assembly facilitates progres-
sive infarct wall thinning and infarct expansion that can lead to
LV dilation, aneurysm formation, and rupture [68, 69].
ECM is composed of structural and nonstructural
matricellular proteins, as well as a proteolytic system of
MMPs and TIMPs [68]. After MI, an elevation in the produc-
tion of structural ECM proteins generates an infarct scar, and
matricellular proteins help to organize the ECM fibrillar struc-
ture as well as regulate the inflammatory and angiogenic
responses. In this review, we summarize the current knowl-
edge on the functions of myofibroblasts, MMPs, TIMPs, and
specific ECM components in the MI-induced LV remodeling,
as well as discuss future research directions to better under-
stand these processes. Dissecting the mechanisms whereby
fibroblasts and ECM molecules coordinate the post-MI re-
modeling response may identify potential interventions to
stimulate an optimal infarct healing response.
Cardiac fibroblasts and myofibroblasts
Cardiac fibroblasts are the most numerous cell types in the
heart, accounting for up to 70 % of total cell numbers in the
normal LV [91]. However, the role of fibroblasts has often been
overlooked in favor of the more studied cardiomyocyte. Recent
studies have focused on the complex and dynamic interaction
between cardiac fibroblasts, cardiomyocytes, and leukocytes in
the development of cardiovascular disease [8]. Under physio-
logical conditions, cardiac fibroblasts provide a mechanical
scaffold and coordinate systolic heart function. Additionally,
myofibroblasts are the main producers of ECM proteins in the
heart and function as local immune modulators [105].
Cell origins and types
The most common technique to identify cell source is the use of
a fate map that represents the developmental history of each cell
in the adult body [134]. Methods for fate mapping include
labeling cells with dyes, creation of chimeric tissues from
different species, detection of specific gene sequences (e.g.,
sex-mismatch transplantation), and the use of transgenic
reporter systems (e.g.,β-galactosidase) [47]. Cardiac fibroblasts
have been tagged using transgenic mouse models, including the
MHC-Cre skeletal muscle cell graft model that generated a
subpopulation of skeletal-cardiac hybrid fibroblast cells, giving
evidence for epithelial–mesenchymal transition origin [93,
135]. Even though the use of transgenic models to fate map
cells is the current state of the art, it is limited since each model
targets only one gene. Amodel where tagged cardiac fibroblasts
from different sources could be visualized in real time would be
ideal but is not yet feasible in adult mammals.
Fibroblasts are widely distributedwithin the body and display
significant differences among organs and tissues. For example,
fibroblasts from the atria respond differently to pathological
stimuli compared with fibroblasts from the ventricle, denoting
evidence of cellular diversity [7]. These differences result from
the fact that cardiac fibroblasts can originate from different
cellular sources depending on the stage of heart development
and cellular context: homeostasis versus injury [33].
Following injury, myofibroblasts are induced by a variety
of cell lineages and are the primary contributor of ECM. In
addition to resident cardiac fibroblasts, myofibroblasts origi-
nate from bone marrow-derived fibrocytes, mesenchymal
stem cells, epithelial/endothelial cells, pericytes, and mono-
cytes (Fig. 1) [55]. Upon injury, resident cardiac fibroblasts
are activated and differentiated into myofibroblasts by a series
of inflammatory mediators and mechanical alterations [115].
Friendenstein and colleagues presented the first in vitro evi-
dence for the bone marrow origin of fibroblasts about 40 years
ago [31, 65]. They cultured bone marrow cells in media with
fetal bovine serum and identified the resulting colonies as
fibroblasts. Circulating cardiac fibroblast progenitor cells de-
rived from the bone marrow have recently been termed
fibrocytes [115]. Mesenchymal stem cells have pluripotent
differentiation potential and are capable of differentiating into
myofibroblasts [10]. Another origin of myofibroblasts is the
epithelial/endothelial–mesenchymal transition (EMT), which
describes tissue generation of myofibroblasts originating from
organ epithelium (epithelial cells) and endothelium (endothe-
lial cells) [54]. Pericytes play an important role in microvessel











Fig. 1 Origins of cardiac myofibroblasts. Cardiac myofibroblasts origi-
nate from a wide array of cell sources, including resident cardiac
fibroblasts, bone marrow-derived fibrocytes, mesenchymal stem cells,
epithelial/endothelial cells, pericytes, and monocytes
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pericytes can also become myofibroblasts [28]. Very recently,
Trial and colleagues showed that monocytes infiltrating the
heart can differentiate into fibroblasts [112]. This demonstra-
tion of conversion between mature cells opens an exciting
new direction for LV remodeling research.
Myofibroblast activation and differentiation
Myofibroblasts are essential for wound healing and have a
contractile phenotype, sharing characteristics of smooth mus-
cle cells [68]. This cell type is normally not present at high
numbers in the healthy myocardium, but are a predominant
cell type in the infarcted tissue after day 3 post-MI.
Myofibroblasts express large amounts of α-smooth muscle
actin (α-SMA), vimentin, desmin, and fibronectin extra do-
main A (EDA) markers [5]. The most commonly used molec-
ular marker for myofibroblasts is α-SMA [41]. Expression of
α-SMA increases myofibroblast contractile activity over 2-
fold in vitro [39]. The mechanism behind this process is still
unclear; however, the α-SMA specific N-terminal amino acid
sequence AcEEED plays a central role in inducing cell con-
tractibility. In vivo and in vitro studies show that delivery of
the peptide AcEEED selectively inhibits α-SMA expression
and reduces myofibroblast contractile activity [40]. Uncon-
trolled proliferation and/or activation ofmyofibroblasts results
in tissue fibrosis. Therefore, identifying the mechanisms of
action of the peptide AcEEED may help to understand the
mechanisms involved in tissue remodeling, particularly in
conditions of pathological fibrosis.
Transforming growth factor (TGF)-β is a major promoter
of myofibroblast activation and differentiation. TGF-β in-
duces the expression of α-SMA, modulates the expression
of adhesive receptors, and enhances the synthesis of ECM
molecules including collagen I and fibronectin EDA [43]. The
pathway leading to TGF-β activation has been extensively
studied. Proteases including plasmin, MMP-2, and MMP-9
cleave latent TGF-β to generate the active form [6].
Thrombospondin (TSP)-1 is also a key TGF-β activator,
which acts by disrupting the noncovalent bond between the
latency-associated peptide and the TGF-β molecule [71, 83].
Active TGF-β binds to TGF-β receptor type II and results in
phosphorylation of receptor-activated Smads. Phosphorylated
Smads (Smads 2, 3, and 4) form heteromeric complexes that
translocate into the nucleus and result in efficient TGF-β
signal transduction [86]. Activation of the Smad3 signaling
pathway has been reported to stimulate ECMprotein synthesis
and TIMP upregulation in myofibroblasts [120].
The capability of TGF-β to induce myofibroblast differen-
tiation is regulated by matricellular and ECM proteins, includ-
ing tenascin-C, periostin, TSP-1, connective tissue growth
factor (CTGF), secreted protein acidic and rich in cysteine
(SPARC), and fibronectin. Tenascin-C, a matricellular protein
that is upregulated post-MI, promotes recruitment of
myofibroblasts in the early stages of myocardial repair
through stimulation of cell migration and differentiation
[110]. Periostin promotes myofibroblast recruitment and col-
lagen synthesis, and periostin null mice have increased rates of
LV rupture post-MI due to reduced collagen deposition [87,
104]. TSP-1 has been associated with myofibroblast matura-
tion and fibrogenesis in a model of pressure-overloaded heart
[128]. CTGF enhances TGF-β-induced fibroblast differentia-
tion into myofibroblasts [19]. SPARC deficiency results in
impaired fibroblast activation and decreased ECM production
post-MI, thus facilitating LV rupture [79]. Serini and col-
leagues showed that fibronectin EDA deposition precedes α-
SMA expression during granulation tissue evolution and dur-
ing in vitro TGF-β fibroblast stimulation and differentiation,
with the degree of myofibroblast differentiation proportional
to the levels of fibronectin EDA [102]. Moreover, a fibronec-
tin EDA blocking antibody inhibits TGF-β induced expres-
sion of α-SMA and collagen I in cultured cardiac fibroblasts,
implying that fibronectin EDA mediates TGF-β-induced fi-
broblast differentiation [102]. From these studies, it is clear
that matricellular proteins regulate several aspects of
myofibroblast function.
Myofibroblast functions
The myofibroblast has two main functions post-MI: provide
mechanical strength to the scar by secreting new ECM pro-
teins to replace the damaged myocardium and stimulating
infarct contraction and produce factors that regulate the in-
flammatory and fibrotic responses. Myofibroblasts directly
contact with ECM proteins through stress fibers at cell-
integrin-matrix junction sites and with other cells via N-
cadherin-type adherens junctions [38, 42]. These junctions
increase myofibroblast contractility that is essential for struc-
tural integrity and support the new matrix to strengthen the
infarct scar.
Post-MI, myofibroblasts migrate into the damaged tissue
and synthesize new ECM. The activation stimuli come from
pro-inflammatory cytokines and hormones, which are re-
leased by inflammatory and resident cells and from changes
in the mechanical microenvironment [91, 111]. FollowingMI,
cardiac fibroblasts respond to the loss of ECM integrity,
increased mechanical stress, and increased levels of platelet-
derived growth factor by adopting a partially differentiated
phenotype known as the proto-myofibroblast [111]. Subse-
quently, myofibroblasts enhance their proliferative and migra-
tory rates, secrete ECM proteins, synthesize MMPs, and reg-
ulate expression of cytokines and growth factors, such as
tumor necrosis factor-α, interleukin (IL)-1, IL-6, and TGF-β
[91].
In summary, myofibroblasts embody a unique, yet devel-
opmentally diverse, population of cells that play a major role
in post-MI LV remodeling. Enhanced understanding of the
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cell source and the myofibroblast regulatory mechanisms can
facilitate the generation of therapeutic targets for this multi-
functional cell type to optimize infarct scar formation and
prevent progression to heart failure.
MMPs
MMPs are a group of proteolytic enzymes consisting of 25
knownmembers. These proteins are generally released in their
zymogen form, with the exception of MMP-11 and MMP-28
[46]. Structurally, the MMPs typically consist of four do-
mains, which include a pro-domain, a catalytic domain, a
hinge region, and a hemopexin domain [121]. MMP-2 and
MMP-9 also have a fibronectin type II-like domain inserted
into the catalytic domain that facilitates collagen cleavage
[121]. With the exception of MMP-23, these enzymes are
activated by a cysteine switch mechanism; disassociation of
cystein-73 residue from zinc atom is required for exposure of
the catalytic site, which is the switch that leads to the activa-
tion of the MMP [117, 121].
MMPs have been categorized into five groups based loose-
ly on in vitro substrate specificity and localization: collage-
nases, gelatinases, stromelysins, matrilysins, and membrane
typeMMPs [89]. The role of MMPs in cardiac repair has been
a focus of our group [46, 63]. In this review, we will focus on
the role of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, MMP-13, MMP-14, and MMP-28, which are the
MMPs that have been evaluated post-MI (Table 1).
MMP-1
MMP-1 (fibroblast collagenase or collagenase-1) was the first
MMP discovered and named in 1966 [85]. MMP-1 has latent
(57/52 kDa) and active (49/37 kDa) forms. MMP-1 can be
expressed myocytes, macrophages, and fibroblasts [63]. Ro-
dents do not express the same MMP-1 gene expressed by
humans but rather have homologous forms MMP-1a and
MMP-1b. MMP-1 cleaves collagen, gelatin, laminin, as well
as non-ECM substrates such as complement C1q, IL-1β, and
tumor necrosis factor-α [63, 121]. MMP-1 activity in the
infarct area has been reported to increase 2 days after MI,
peaking at day 7 [17]. This expression pattern indicates that
MMP-1 may regulate the late inflammatory response and
ECM turnover. In patients with acute MI, plasma MMP-1
levels are positively associated with LV dysfunction and dila-
tion, implying that increased collagenolytic activity facilitates
impairment of LV function [88].




1 ↑ Myocyte, macrophage, and fibroblast Predicts LV dysfunction and dilation in MI patients
2 ↑ Myocyte, fibroblast, myofibroblast, vascular smooth
muscle cells, and endothelial cell
↓ survival, ↑ LV rupture, and ↑ macrophage infiltration
3 ↑ Myocyte, fibroblast, and macrophage Correlates with LV dysfunction and mortality inMI patients, and
activates MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, and
MMP-13
7 ↑ Myocyte and macrophage ↓ survival, ↓ conduction velocity, and activates MMP-1,
MMP-2, MMP-7, and MMP-9
8 ↑ Neutrophil and macrophage ↑ LV rupture, ↑ neutrophil infiltration, and degrades collagen
9 ↑ Myocyte, fibroblast, neutrophil, macrophage, vascular
smooth muscle cell, and endothelial cell
↑ LV dilation, ↓/↑ LV function, ↑/↓ inflammation, and ↑ collagen
deposition
13 ↑ Fibroblast and macrophage Activates MMP-9
14 ↑ Myocyte, fibroblast, and myofibroblast ↓ LV function, ↓ survival, ↑ fibrobsis, and activates MMP-2 and
MMP-13
28 ↓ in myocyte ↑in
macrophage
Myocyte and macrophage ↑ LV function, ↓ LV rupture, ↓ mortality, ↑ M2 macrophage
polarization, and ↑ collagen deposition and cross-linking
TIMPs
1 ↑ Myocyte and fibroblast ↓ LV dilation
2 ↑ Fibroblast ↓ LV dilation, ↑ LV function, ↓ infarct size, ↓ inflammation, and
↓ collagen disorganization
3 ↓ Fibroblast ↓ LV dilation, ↑ LV function, ↓ LV rupture, ↓mortality, ↓ infarct
size, ↑ myofibroblast number, ↑ collagen deposition, and ↓
MMP activity
4 ↓ Myocyte ↓ LV rupture and ↓ mortality
MMPs matrix metalloproteinases, TIMPs tissue inhibitors of metalloproteinases, MI myocardial infarction, LV left ventricle
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MMP-2
MMP-2 (gelatinase A or 72 kDa gelatinase) has a 72-kDa
latent and a 66/62-kDa active form [46]. MMP-2 is expressed
by myocytes, fibroblasts, myofibroblasts, vascular smooth
muscle cells, and endothelial cells [63]. Substrates for
MMP-2 include both extracellular and intracellar proteins,
including aggrecan, citrate synthase, elastin, fibronectin, fu-
sion protein, IL-1β, prolysyl oxidase, and other MMPs such
as MMP-1, MMP-9, and MMP-13 [46]. Myosin light chain
and troponin I are intracellular substrates for MMP-2 and
highlight the interaction between some MMPs and
cardiomyocytes [63, 98]. In animal studies, MMP-2 activity
peaks by day 7 and declines to normal levels by day 14 after
MI in the LV infarct area [63]. MMP-2 null mice subjected to
MI have reduced macrophage infiltration in the infarct region,
a lower rate of LV rupture, and improved survival in compar-
ison to wild type mice [76]. This suggests a role for MMP-2 in
regulating the entry of inflammatory cells in the infarcted area
post-MI. Reduced ECM degradation in the absence of MMP-
2 may explain the reduced rupture phenotype observed in
MMP-2 null mice. In humans, post-MI plasma MMP-2 levels
were surprisingly inversely correlated with LV volumes, and a
larger cohort study is warranted before these results are
interpreted [107].
MMP-3
MMP-3 (stromelysin-1) has 59/57 kDa latent and 48 kDa
active forms. MMP-3 has casein and proteoglycan degrading
properties and is expressed by myocytes, fibroblasts, and
macrophages [63, 121]. MMP-3 activates MMP-1, MMP-3,
MMP-7, MMP-8, MMP-9, and MMP-13, indicating crosstalk
within the family members [121]. MMP-3 increases within
3 days post-MI in rats and declines over the next 14 days [64,
95]. In acute MI patients, plasmaMMP-3 levels are positively
associated with patient age and sex (higher in male patients),
creatinine levels, and hypertension, but negatively correlate
with LV ejection fraction [51]. As a result, MMP-3 has been
suggested to be an independent predictor of LV systolic dys-
function and mortality in MI patients [51].
MMP-7
MMP-7 (matrilysin) is the smallest MMP, with 28 kDa latent
and 19 kDa active forms. It is mainly expressed by the
myocyte and macrophage. MMP-7 cleaves several ECM pro-
teins and primarily activates MMP-1, MMP-2, MMP-8, and
MMP-9 [121]. Post-MI, MMP-7 increases robustly in macro-
phages [121]. Our lab showed that MMP-7 deficiency im-
proves mouse survival post-MI, but not by attenuating LV
dilation [60, 63]. Interestingly, MMP-7 deficiency protected
mice from reduced conduction velocity, and MMP-7 was
shown to directly bind and process connexin-43. Using a
proteomic strategy, we identified fibronectin and tenascin-C
as additional in vivo MMP-7 substrates in the infarcted LV
[15]. In addition, MMP-7 may indirectly regulate the expres-
sion of peroxiredoxin-1, peroxiredoxin-2, and peroxiredoxin-
3 through nonenzymatic mechanisms [15].
MMP-8
MMP-8 has 64 kDa latent and 58 kDa active forms. Although
originally named neutrophil collagenase, MMP-8 is actually
secreted by both neutrophils and macrophages [63]. MMP-8
cleaves fibrillar collagens by binding collagen type I α1 and
α2 chains, thus promoting cell migration [59]. MMP-8
mRNA increases as early as 6 h. after MI. MMP-8 protein
levels increase 2 weeks post-MI at both border and infarcted
regions, and persist through 4 months, indicating its involve-
ment in the early and late remodeling responses [90]. MMP-8
levels are higher in patients with LV rupture than those with-
out rupture post-MI, indicating that MMP-8 may promote
infarct rupture in humans by degrading collagen [116].
MMP-9
MMP-9 (gelatinase B or 92 kDa gelatinase) is one of the first
MMPs found to be expressed in infiltrating neutrophils and
macrophages present in the infarct area [46, 70]. MMP-9 is
also expressed by myocytes, fibroblasts, vascular smooth
muscle cells, and endothelial cells- although at log-fold lower
amounts compared with the infiltrating leukocytes [129]. In
humans, MMP-9 has 92 kDa latent and 88 kDa active forms.
In mice, MMP-9 has 105 kDa latent and 95 kDa active forms.
MMP-9 is known to degrade a variety of proteins, including
aggrecan, collagen, elastin, fibronectin, galectin-3, IL-1β,
laminin, SPARC, as well as activate TGF-β1 by processing
the latent TGF-β binding protein [46, 133]. An increase in
MMP-9 levels correlates with the development of LV dys-
function [3]. Targeted deletion of the MMP-9 gene in mice
leads to decreased collagen accumulation and attenuated LV
dilation post-MI [24]. Of note, overexpression ofMMP-9 only
in macrophages also leads to beneficial effects post-MI (e.g.
attenuated inflammatory response and improved LV func-
tion), suggesting various levels of regulation of post-MI
healing process by MMP-9, depending on cell source and
timing of expression [132].
MMP-13
MMP-13 (collagenase-3) has 60 kDa latent and 48 kDa active
forms. Fibroblasts and macrophages are reported to express
MMP-13 [46, 63]. MMP-13 mRNA amounts remain stable
following MI through 16 weeks in the rat, but MMP-13
activity increases 72 h. post-MI, indicating that MMP-13
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activity can increase without affecting gene expression [46].
Not much is known about MMP-13 functions, mechanism of
action, or how it affects LV remodeling post-MI; however, it is
known to stimulate MMP-9 activation [46, 121].
MMP-14
MMP-14 (membrane type 1 MMP; MT-1 MMP) has 65 kDa
latent and 54/45/40 kDa active forms [63]. MMP-14 is
expressed by card iomyocy tes , f ib roblas t s , and
myofibroblasts. It cleaves collagen, fibronectin, gelatin, and
can activate MMP-2 and MMP-13 [121]. MMP-14 increases
20-fold at 3 days post-MI and 50-fold at 16 days post-MI in
non-infarcted LV regions, indicating critical roles in both early
and late remodeling events [18, 61, 63]. Furthermore, in
animal studies the increase in MMP-14 post-MI is associated
with significant cardiac fibrosis, reduced LV function, and
lower survival [63].
MMP-28
MMP-28 (epilysin) is the newest identified member of the
MMP family and was first cloned in 2001 [67]. The furin-like
proprotein convertase processes the 58 kDa pro-form of
MMP-28 to its 48 kDa active form, which is then secreted
into the extracellular environment [69]. The 3 known sub-
strates for MMP-28 are casein, Nogo-A (a myelin compo-
nent), and neural cell adhesion molecule-1 [73, 121]. MMP-
28 is highly expressed in the normal heart, suggesting roles in
normal tissue homeostasis. However, MMP-28 null mice do
not show an abnormal heart phenotype in the unstressed
setting [69]. We have recently shown that MMP-28 derived
from macrophages increases at 5 days post-MI, although total
levels of the protein in the infarct decrease due to the loss of
myocytes [69]. MMP-28 deletion worsens LV dysfunction
and mortality as a result of increased cardiac rupture rate,
which is strongly associated with impaired M2 macrophage
activation and ECMdeposition [69]. This study introduces the
idea that not every MMP is detrimental and reinforces the
concept that selective MMP inhibitors are warranted to inhibit
individual MMPs.
TIMPs
TIMPs are potent endogenous inhibitors of MMP activity and
include four homologous members: TIMP-1, TIMP-2, TIMP-
3, and TIMP-4. TIMPs play important roles in LV remodeling
post-MI by directly inhibiting MMP activity and indirectly
regulating remodeling processes (Table 1).
TIMP-1
TIMP-1, a 29-kDa glycoprotein, is secreted by myocytes and
fibroblasts. TIMP-1 mRNA increases in the infarct region
within 6 h. following MI and declines after 2 days with no
detectable alterations in regions remote from the infarct [17,
63]. Compared with wild-type counterparts, TIMP-1 knock-
out mice show larger LV volumes, which can be reversed by
MMP inhibition [44]. This indicates that TIMP-1-dependent
beneficial effects are mediated by inhibiting MMP activity.
TIMP-2
TIMP-2 (28 kDa), which is primarily secreted by fibroblasts,
is highly expressed in the normal myocardium. In addition to
suppressing MMP activity, TIMP-2 is the only TIMP that is
required for cell surface activation of pro-MMP2, suggesting
both anti- and pro-activating roles [49]. TIMP-2 mRNA in-
creases post-MI whereas the protein level does not undergo
major change. Kandalam et al showed that the absence of
TIMP-2 post-MI was associated with greater infarct expan-
sion and LV dilation, worse LV dysfunction, and more severe
inflammation and collagen disarray [49]. This could bemainly
attributed to its inhibitory action on MMP-14. Therefore,
TIMP-2 supplementation may provide a potential strategy in
attenuating LV remodeling post-MI.
TIMP-3
TIMP-3 (24 kDa) is ECM bound and has been shown to be a
powerful inhibitor of all MMPs. TIMP-3 is highly expressed
in the normal heart (secreted by fibroblasts). TIMP-3 protein
levels decrease in both animals and patients withMI. Post-MI,
TIMP-3 deletion has been demonstrated to increase mortality
as a result of enhanced cardiac rupture, greater infarct expan-
sion, exacerbated LV dilation, and worse LV dysfunction [48].
TIMP-3 null mice subjected to MI also showed reduced
collagen synthesis, disorganized collagen deposition, de-
creased myofibroblast number in the infarct area, and in-
creased MMP activity [37, 48]. MMP inhibition reverses the
effects observed in the TIMP-3 null mice. Thus, proteolytic
activity early post-MI is a promoting factor for subsequent
adverse LV remodeling and dysfunction, and timing of inter-
vention to improve the LV response to MI may be critical in
producing a beneficial outcome [48].
TIMP-4
In addition to having a 24-kDa form, TIMP-4 has a 28-kDa
glycosyla ted form repor ted to be expressed by
cardiomyocytes [63]. Unlike other TIMPs, TIMP-4 mRNA
does not increase post-MI but protein levels reportedly de-
crease in weeks 1 and 4 post-MI [9, 118]. Similarly to other
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TIMPs, TIMP-4 deletion results in increased LV rupture and
mortality, which can be prevented by MMP inhibition [53].
Plasma TIMP-4 levels, but not TIMP-1 or TIMP-2 plasma
levels, has been suggested to predict LV remodeling in MI
patients [124].
Taken together, studies clearly show the importance of
MMPs and TIMPs post-MI and demonstrate that their protein
and activity levels change during different phases of the
wound healing process to regulate LV remodeling. Additional
studies that explore the temporal and spatial patterns of MMP
and TIMP expression will expand our understanding of the
mechanisms of LV remodeling.
Structural ECM
Fibrillar collagens, fibronectin, and laminins comprise the
structural component of the ECM, which is important in
maintaining architecture and preserving normal LV function
[68]. Several functional domains within structural ECM or
ECM-derived fragments serve critical roles in LV remodeling
in the MI setting (Table 2) [68].
Collagens
Collagens are the most abundant ECM proteins in the LV; and
of 28 subtypes, collagen type I is the most abundant [12].
Following MI, collagen types I, III, IV, V, and VI increase in
the infarct region, covering approximately 30 and 60 % of the
infarct area at days 7 and 21 post-MI, respectively [62, 103].
In particular, collagen types I and III are major components of
the myocardium scar [103]. The cardiac fibroblast is the major
source of collagens in the post-MI setting. Proper collagen
accumulation and assembly is essential for preventing pro-
gressive LV dilation post-MI. Collagen proteolysis post-MI is
regulated by multiple MMPs that have collagenolytic activity,
including MMP-1, MMP-2, MMP-8, MMP-9, MMP-13, and
MMP-14. The role of collagen peptides that are generated by
MMP activity during LV remodeling, however, has not fully
clarified.
Circulating collagen peptides are commonly used as cardi-
ac biomarkers of myocardial fibrosis and as a prognosticator
of cardiac function. Collagens are synthesized as procollagen
forms, which are secreted into the interstitial space where they
undergo cleavage of their end-terminal propeptide sequences
to enable collagen fiber formation [123]. The collagen termi-
nal propeptides (e.g., amino (N)-propeptide and carboxy (C)-
propeptide) are released into the circulation by the action of
specific procollagen N- and C-proteinases [122]. The most
commonly used biomarker for quantification of collagen type
I synthesis is its 100 kDa C-terminal propeptide, with serum
levels positively associated with diastolic dysfunction [74].
The N-terminal propeptide of collagen type III is a 42-kDa
peptide that is widely used as a marker for collagen type III
synthesis [97]. Elevated serum levels of this peptide have been
positively correlated with increased mortality risk and heart
failure [16].
The non-fibrillar collagens, such as collagen types IV and
V, organize the basement membrane structure. Collagen type
IV levels increase in both infarcted and non-infarcted area
post-MI [103]. Collagen type VI increases in the infarcted area
Table 2 Roles of ECM proteins increased post-MI
Name Roles
Structural ECM
Collagen I and III Scar components and correlates with diastolic
dysfunction and mortality risk
Collagen IVand V Basement membrane components
Collagen VI ↓ LV function, ↑ apoptosis, and ↑ collagen
deposition
Fibronectin EDA ↑ LV dilation, ↓ LV function, ↑ inflammation, ↑
MMP activity, and ↑ myofibroblast numbers
Laminin Basement membrane component and negative
correlation with LV function
Matricellular proteins
CCN-1 ↑ apoptosis, ↓ inflammation, and ↓ fibrosis in
other models
CCN-2/CTGF ↓ infarct size in an ischemia/reperfusion model
CCN-4/WISP1 ↓ myocyte apoptosis, ↑ hypertrophy, and ↑
fibroblast proliferation (in vitro)
Osteopontin ↓ LV remodeling, ↓ LV dilation, ↑ collagen
deposition, and ↑ angiogenesis
Periostin ↑ LV function, ↓ LV rupture, ↓ fibrosis, and ↑
regeneration
SPARC ↑ LV function, ↓ LV rupture, ↓ mortality, ↑
macrophage infiltration, and ↑ scar
organization
Tenascin-C ↑ LVremodeling, ↓ LV function, ↑ fibrosis, and ↑
fibroblast function
Thrombospondin-1 ↓ LV remodeling, ↑ LV function, and ↓
inflammation
Proteins with matricellular functions
Galectin-3 Positive correlation with infarct size, heart
failure, and 30-day mortality
Biglycan ↓ LV dilation, ↑ LV function, ↓ LV rupture, ↓
mortality, ↑ LV tensile strength, and ↑ scar
organization
Decorin ↓ LV dilation, ↑ LV function, ↓ infarct size, ↓
hypertrophy, and ↑ scar organization
Syndecan-1 ↓ LVremodeling, ↑ LV function, ↓ inflammation,
↓ MMP activity, and ↑ scar quality
Syndecan-4 ↑ LV function, ↓ LV rupture, ↓ mortality, ↑
inflammation, and ↑ ECM deposition
Vitronectin Positive correlation with MI severity
ECM extracellular matrix, MI myocardial infarction, LV left ventricle,
CTGF connective tissue growth factor, SPARC secreted protein acidic and
rich in cysteine
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within days post-MI, and then accumulates in both infarct and
non-infarct area [66]. Surprisingly, absence of collagen type
VI improves LV function, structure, and remodeling after MI
by inhibiting apoptosis and collagen accumulation [66]. This
indicates that collagens not only constitute the major compo-
nents of the scar, but also regulate cardiac healing.
Fibronectin
Fibronectin is a multifunctional adhesive glycoprotein pro-
duced by fibroblasts, macrophages, and endothelial cells in
response to tissue injury. Fibronectin regulates cell shape and
movement. For example, fibronectin guides macrophages into
wound areas. Fibronectin contains an alternatively spliced
exon encoding type III repeat EDA that is only expressed
during development or after injury [68]. EDA can bind both
toll-like receptor-2 and toll-like receptor-4 and activate mono-
cytes in vitro [100]. EDA injection into murine joints activates
nuclear factor-κB, resulting in enhancement of the inflamma-
tory response [35]. EDA also regulates cell adhesion and
proliferation and stimulates TGF-β pathway, which leads to
generation of the myofibroblast phenotype [58, 102]. Interest-
ingly, EDA-null mice with MI exhibit less LV dilation and
better LV function compared with wild-type mice [2]. EDA-
null mice also showed the reduced inflammation, MMP-2 and
MMP-9 activities, and myofibroblast differentiation. These
results suggest that EDA plays a critical role in adverse LV
remodeling post-MI. Fibronectin also contains the extra do-
main B (EDB), which is expressed during embryogenesis
[32]. Although the role of EDB in the MI setting has not been
evaluated, EDB is highly expressed in normal tissue during
angiogenesis, suggesting a role for EDB during LV remodel-
ing following MI. Recently, using a proteomic approach, we
showed that fibronectin is an in vivo substrate of bothMMP-7
andMMP-9 [15, 133]. These findings expand our understand-
ing of protective mechanisms when MMP-7 or MMP-9 is
deleted in the MI setting.
Laminins
Laminins are essential components of basement membranes
and are composed of α, β, and γ chains. At least 15 laminin
isoforms have been identified to date. Laminin is the first
ECM to appear in the embryo. Laminin anchors cells to the
ECM and can bind to multiple receptor proteins, such as
collagen type IV, dystroglycan, entactin, heparin, heparin
sulfate, integrins, and syndecans [108]. Laminin levels in-
crease in the infarct area at day 3 post-MI and peak at days 7
to11 [82]. In theMI setting, laminin is detected throughout the
infarct region, and this wide distribution suggests that the role
of laminin post-MI exceeds the maintenance of basement
membranes [82]. The expression pattern of laminin post-MI
is similar to that of collagen type IV [82]. Serum
concentrations of laminin and collagen type IV in acute MI
patients are higher than in patients with stable or no coronary
artery disease [22], and correlate with the severity of LV
dysfunction [22]. This suggests that serum laminin and colla-
gen type IV levels may be surrogate markers of ECM remod-
eling post-MI.
Matricellular proteins
Matricellular proteins are a family of nonstructural matrix
proteins that are capable of regulating a variety of biological
functions by interacting with cell surface receptors, growth
factors, proteases, and structural matrix [4]. Under normal
conditions, matricellular proteins are generally present at very
low expression levels. Following injury (e.g., MI), their ex-
pression increases substantially, implying a role in the repair
response [68]. Matricellular proteins consist of CCN family
members, osteopontin, periostin, SPARC, tenascins, and
TSPs. Their roles in MI-induced LV remodeling have been
extensively reviewed by several groups (summarized in Ta-
ble 2) [29, 68]. Some proteins, such as galectins, small
leucine-rich proteoglycans (SLRPs), syndecans, and
vitronectin, share matricellular structure and/or functions,
but have not been assigned to the family of matricellur pro-
teins. In the following section, we will summarize current
knowledge on their functions in MI-induced LV remodeling.
Galectin-3
Galectins are composed of a family of evolutionarily con-
served glycan-binding proteins and can bind to the carbohy-
drate portion of glycoproteins and glycolipids in the cell
surface. Based on their structure and the number of carbohy-
drate recognition domain, galectins have been divided into
three groups: (1) prototype galectins: galectin-1, galectin-2,
galectin-5, galectin-7, galectin-10, galectin-11, galectin-13,
and galectin-14; (2) tandem-repeat galectins: galectin-4,
galectin-6, galectin-8, galectin-9, and galectin-12; and (3)
chimera galectin-3 [131].
Among those, galectin-3 is the most widely investigated
member associated with cardiovascular disease. Galectin-3 is
a β-galactoside binding lectin primarily expressed by activat-
ed macrophages and serves as a novel marker for inflamma-
tion and fibrosis [25]. Weir and colleagues reported that plas-
ma galectin-3 levels increased significantly following MI
(mean, 46 h after MI) and was positively associated with
remodeling parameters in patients with supra-median baseline
LV ejection fraction (>49.2 %) but not when LV ejection
fraction was ≤49.2 % [125].
In patients undergoing primary percutaneous coronary in-
tervention for ST elevation MI, circulating galectin-3 levels
were significantly higher than in healthy subjects, and
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elevated circulating level of galectin-3 was the strongest inde-
pendent predictor of the combined 30-day major adverse
clinical outcome (defined as advanced congestive heart failure
or 30-daymortality) [114]. Elevated galectin-3 levels 4months
after acute MI are associated with larger infarct sizes, lower
global myocardial function as well as with higher concentra-
tions of NT-pro brain natriuretic peptide, highlighting the
potential of galectin-3 as a biomarker of adverse remodeling
after acute MI [78]. In patients with first MI treated with
primary percutaneous coronary intervention, serum galectin-
3 levels were an independent predictor for re-infarction [109].
These studies demonstrate the utility of galectin-3 in assessing
late phases of LV remodeling after MI.
Small leucine-rich proteoglycans
The SLRPs are a family of SLRPs that are divided into five
classes based on homologies at both the genomic and protein
levels [14]. SLRPs have a central domain termed tandem
leucine-rich repeats, which can bind to innate immune recep-
tors. SLRPs act as endogenous danger signals, known as
damage-associated molecular patterns, which activate the in-
nate immune system and regulate sterile inflammation-
associated disease [30]. Of the ten family members, biglycan
and decorin are well investigated regarding their roles in
cardiovascular disease. Biglycan and decorin bind to collagen
types I, II, III, and VI, and regulate collagen fibrillogenesis
and fibril diameter [23]. The decorin binding site on collagen
type I has been identified near the C terminus, very close to
one of the major intermolecular cross-linking sites of collagen
heterotrimers [50].
Post-MI, cardiac biglycan expression is significantly up-
regulated peaking at day 7, denoting a possible role in cardiac
repair [127]. In animal studies, biglycan deficiency led to
increased mortality rates after MI as a result of LV rupture.
The biglycan null mice also exhibited aggravated LV dilation
and worse LV function at 21 days post-MI [127]. Ex vivo
measurements demonstrated that LV tensile strength was
compromised, attributed to impaired collagen matrix organi-
zation [127]. Colocalization of biglycan with collagen type I
in the infarct region implicates biglycan in regulation of
collagen deposition and appropriate cross-linking [130].
Therefore, biglycan is required for stable collagen assembly
and scar formation to preserve LV function. Compared with
wild-type, biglycan null cardiac fibroblasts exhibited en-
hanced proliferation and increased TGF-β receptor II expres-
sion and Smad2 phosphorylation. Biglycan deficiency in-
creased fibroblast transformation to myofibroblast, character-
ized by increased incorporation of α-SMA into stress fibers,
formation of focal adhesions, and contraction of collagen gels
[80]. Neutralizing TGF-β activity reversed the pro-
proliferative and myofibroblastic phenotype in the absence
of biglycan [80]. This suggests that biglycan regulation of
fibroblast phenotype and function is dependent on TGF-β
signaling.
After MI, decorin deletion resulted in a wider distribution
of collagen fibril sizes, resulting in a less organized and looser
packed scar [126]. As such, decorin null mice exhibited a
significant increase in scar size and right ventricular hypertro-
phy, as well as aggravated LV dilation and dysfunction [126].
These data demonstrate that decorin is required for proper
collagen assembly, and that its absence leads to disorganized
scar formation.
Syndecans
Syndecans are highly conserved transmembrane heparan sul-
fate proteoglycans and include four family members:
syndecan-1 (syndecan), syndecan-2 (fibroglycan), syndecan-
3 (N-syndecan), and syndecan-4 (ryudocan and amphiglycan).
Structurally, syndecans are composed of an extracellular
ectodomain, a transmembrane domain, and a short cytoplas-
mic domain. The ectodomain can be shed from cells and
become a soluble form, which is the reason why syndecans
have been occasionally considered matricellular proteins [29,
96]. Syndecans bind to a wide range of ECM proteins, growth
factors, chemokines, and anticoagulant proteins by heparan
sulfate glycosaminoglycan chains, playing critical roles in
regulation of tissue injury and repair [11].
FollowingMI in experimental animals, syndecan-1 expres-
sion in the LV is upregulated at 24 h, peaks at 7 days and
declines thereafter [119]. Syndecan-1 deletion leads to adverse
LV remodeling and dysfunction, accompanied by increased
inflammation and activity of MMP-2 and MMP-9, decreased
tissue transglutaminase activity, as well as increased collagen
fragments and disorganization in mice subjected to MI [119].
In concordance, adenoviral gene expression of syndecan-1
rescued the effects observed in the absence of syndecan-1.
These data suggest that increased syndecan-1 afterMI protects
from excessive inflammation and adverse infarct remodeling.
A recent study showed that increased serum concentration of
soluble syndecan-1 after MI was due to its increased expres-
sion in the infarcted myocardium [56].
Elevated plasma syndecan-4 levels in MI patients and the
existence of syndecan-4 in the infarct region attracted research
interest in investigating its role in MI-induced LV remodeling
[52, 57]. Syndecan-4 null mice do not show morphological
and functional cardiac phenotype changes under normal con-
ditions [75]. However, syndecan-4 deletion results in worse
LV function and increased cardiac rupture and mortality. The
potential mechanisms are associated with reduced inflamma-
tion, impaired granulation tissue formation, and decreased
ECM deposition in the infarct region [75]. In vitro,
syndecan-4 deficiency results in inhibition of fibronectin-
induced, but not TGF-β1-induced, fibroblast differentiation
into myofibroblasts. The shed form of syndecan-4 acts as a
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dominant-negative inhibitor of endogenous syndecan-4 sig-
naling. Accordingly, overexpression of the syndecan-4 shed
form mimics the effects observed when syndecan-4 is deleted
[75]. In summary, both syndecan-1 and syndecan-4 exert
protective roles in the MI setting by containing the inflamma-
tory reaction and modulating ECM deposition.
Vitronectin
Vitronectin is an adhesive glycoprotein with multiple func-
tions including blood coagulation, complement activation,
binding to proteoglycans, and modifying the ECM [92]. In
addition, vitronectin regulates cell differentiation, prolifera-
tion, migration, and morphogenesis [136]. Vitronectin can
bind to a number of ligands/receptors, such as the urokinase
receptor, integrin type cell adhesion receptors, growth factors,
proteoglycans, plasminogen activator inhibitor, and high mo-
lecular weight kininogen [72, 92, 136]. The urokinase receptor
regulates monocyte adhesion by direct binding to vitronectin,
indicating a key role of vitronectin in regulating inflammation
[77]. Plasma vitronectin concentration is elevated in patients
with coronary artery diseases, showing a positive correlation
with the extent of disease [26]. Another clinical trial showed
that a higher percentage of patients with baseline vitronectin
of ≥49.7 μg/mL had major adverse cardiovascular events
(e.g., death,MI, or urgent revascularization) than patients with
vitronectin of <49.7 μg/mL at 30 days [21]. Moreover, when
baseline variables not predictive of major adverse cardiovascular
event (e.g., troponin positive, history of congestive heart failure,
diabetes, history of hypertension, and smoking status) were
excluded from the multivariate model, only baseline vitronectin
of ≥49.7 μg/mL and history of MI remained [21]. This indicates
that vitronectinmay serve as an independent predictor of adverse
cardiovascular outcomes following acute stenting.
Matricryptins
Matricryptins, biologically active fragments of the ECM, are
generated from various mechanisms including enzymatic deg-
radation, protein multimerization, absorption, cell-mediated
mechanical forces, and denaturation [68]. Matricyrptins can
be generated from any protein found in the extracellular space.
Matricryptins regulate cell migration, proliferation, differenti-
ation, morphogenesis, survival, ECM assembly, angiogenesis,
tissue repair, and the inflammatory reaction [68, 94]. For
example, neutrophils exert chemotaxis to fragments of colla-
gen type IV [101]. Conversely, a matricryptin peptide from the
α3 chain of collagen IV suppresses neutrophil activation [81].
MMP-9 cleaves the α3 chain of collagen type IV to produce
tumstatin, which inhibits angiogenesis [36]. In addition,
MMPs are reported to cleave collagen IV, generating both
anti- and pro-angiogenic fragments [13]. These reports
suggest that collagen peptides have key biological activity in
regulating post-MI LV remodeling. In the post-MI setting,
endostatin, a matricriptin generated from collagen type XVIII,
is elevated, and neutralization of endostatin exacerbates LV
remodeling and dysfunction [45].
Fibronectin fragments stimulate monocyte migration and
cause a positive feedback loop by increasingMMP production
[99]. In addition, macrophages activated with fibronectin
fragments enhance the survival of injured cardiac myocytes
[113]. Degradation of laminin by neutrophil elastase generates
fragments that are chemotactic for neutrophils, thus establish-
ing a positive feedback loop for neutrophil recruitment [84].
Laminin α1 fragment stimulates macrophage expression of
MMP-9, and laminin α5 peptide is reported to induce a wide
range of cytokines in macrophages leading to a chemotactic
response [1, 27]. These data indicate that laminin and its
fragments may play important roles in the inflammatory re-
sponse post-MI. Research has just scratched the surface of
matricryptin roles in the post-MI LV.
Future directions
Myofibroblasts, as the major source of ECM, are indispens-











Fig. 2 The mechanisms of ECM regulation of LV remodeling post-MI.
Following MI, increased myofibroblasts secrete abundant ECM proteins.
Structural ECM mainly constitutes the reparative scar. MMPs primarily
derived from leukocytes degrade ECM constituents and suppress ECM
synthesis, which, in turn, is inhibited by TIMPs. Nonstructural
matricellular proteins modulate leukocyte infiltration and function and
affect structural ECM assembly. In addition, matricryptins, biologically
active fragments of ECM, are formed by MMP degradation of ECM to
influence several aspects of LV remodeling
Table 3 Areas of research for future directions
1. Fibroblast and myofibroblast post-MI phenotypes, as spatial and
temporal variations in phenotypes may explain functional differences
in LV remodeling responses
2. Expression patterns and roles of the multitude ofMMPs not yet studied
3. Identification and characterization of fragments derived from ECM and
non-ECM substrates
4. Expression patterns and roles of ECM constituents
MImyocardial infarction, LV left ventricle,MMPsmatrix metalloprotein-
ases, ECM extracellular matrix
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myofibroblast activation and function may stimulate proper
wound healing response, thus attenuating adverse or excessive
LV remodeling and preserving LV function. Balanced struc-
tural ECMdeposition and breakdown limits infarct expansion,
LVaneurysm and rupture, and LV wall stiffness. This process
is tightly regulated by MMP activity, which in turn is con-
trolled by TIMPs. Nonstructural matricellular proteins modu-
late inflammation, angiogenesis, and scar formation by direct
binding to cell surface receptors and matrix. The sophisticated
ECM networks crosstalk with each other, with inflammatory
cells and mediators, to coordinate cardiac repair process
(Fig. 2) [29, 68].
Despite advances over the past two decades in understand-
ing the mechanisms of LV remodeling post-MI, additional
studies are still needed to further clarify several important
aspects (Table 3). First, mapping the phenotypes of fibroblasts
isolated from infarct hearts at different time points will pro-
vide clues to their roles in coordinating the ECM response.
Second, the temporal and spatial expression, cellular source,
and function of many MMPs after MI have not yet been
studied. For example, of the 25 identified MMPs, the role of
16 MMPs in the MI setting is presently unknown. Third, a
more inclusive list of MMP substrates may provide additional
insights, particularly for the non-ECM molecules (e.g., cyto-
kines and chemokines), activated or deactivated by MMPs
[46]. This broadens the field of MMP activity that directly
links with the inflammatory response. Proteomics strategies
that target inflammatory mediators and ECM can provide a
more thorough and high throughput identification of novel
ECM and non-ECM substrates [20]. Moreover, the biological
functions of the fragments derived from substrate cleavage
need to be characterized. Finally, more information on the
individual ECM constituents and their roles in the remodeling
response is needed. There are likely hundreds of different
ECM proteins in the post-MI LV. The individual roles as well
as their functions as part of the entire remodeling response
remain to be examined [68]. While in vitro experiments study
the roles of individual component, additional knowledge re-
garding the interaction of various components in regulating
remodeling in the context of the entire post-MI myocardium is
needed. This will allow us to design inhibitors or agonists that
have the best translational potential.
Conclusions
In conclusion, MI remains a major cause of congestive heart
failure. The extent of MI-induced LV remodeling is greatly
dependent on the ECM regulation. Elucidating how the ECM
regulates this transition of MI to heart failure will identify
novel intervention targets that may help to stimulate an opti-
mal wound healing response.
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